FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Dermata Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Dermata Therapeutics, Inc. (DRMAW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisDRMAW
DRMAW
Dermata Therapeutics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
DRMAW
Home🔹Stocks🔹Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc.

DRMAW•NASDAQ

Dermata Therapeutics, Inc.

DRMAW•NASDAQ
Market cap
$2.73K
Sentiment

Your view on DRMAW

Mkt Cap
$2.73K
Sentiment
Your view
DRMAW
Dermata Therapeutics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
DRMAW
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Dermata Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Gerald T. Proehl
Headquarters
3525 Del Mar Heights Road, San Diego, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Gerald T. Proehl
Headquarters
3525 Del Mar Heights Road, San Diego, CA, US
Description

Dermata Therapeutics, Inc., a biotechnology company in the clinical development stage, is headquartered in San Diego, California, and was established in 2014. The firm's core mission is to develop innovative treatments for a variety of dermatological and cosmetic skin conditions. Its flagship investigational product, DMT310, is a topical formula applied once weekly that is currently undergoing clinical trials. This primary compound is being evaluated for its effectiveness against acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. Additionally, the company is advancing DMT410, which is intended to address hyperhidrosis (excessive sweating) and other aesthetic concerns.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for Dermata Therapeutics, Inc., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Dermata Therapeutics, Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Dermata Therapeutics, Inc.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Dermata Therapeutics, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Dermata Therapeutics, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Dermata Therapeutics, Inc. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold Dermata Therapeutics, Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by Dermata Therapeutics, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Dermata Therapeutics, Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Dermata Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Dermata Therapeutics, Inc.. Press releases and market coverage, newest first.

News

Latest Market News